v1
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Identifier:nobleid.org/w1/20260515/DA8CDCAB
Type:Journal Article
0 views
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →